News

Garadacimab up for approval as HAE therapy in US, Europe

The monthly under-the-skin injection therapy garadacimab will be considered for approval for treating hereditary angioedema (HAE) in both the U.S. and the European Union. Developer CSL Behring announced that both the U.S. Food and Drug Administration and the European Medicines Agency have agreed to review applications of the therapy…

Deucrictibant reduces rate of HAE swelling attacks in Phase 2 trial

Prophylactic, or preventive, treatment with deucrictibant significantly reduced the rate of swelling attacks among adults with hereditary angioedema (HAE) in a Phase 2 clinical trial. “These study results, together with the compelling data from our on-demand program, further strengthens our confidence that deucrictibant can become the preferred option…

Argentina approves oral Orladeyo to prevent HAE attacks

Argentina’s regulatory body has approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) to prevent swelling attacks in adults and adolescents, ages 12 and older, who have hereditary angioedema (HAE). The decision by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) comes a few months after the approval of…

Takhzyro approved in Europe for HAE patients as young as 2

The European Commission has expanded the approval of Takhzyro (lanadelumab) to include children with hereditary angioedema (HAE) as young as 2 years of age. This makes Takhzyro the first routine preventive, or prophylactic, treatment for HAE attacks to be approved for patients younger than 6 in the European…

NTLA-2002 earns orphan drug designation in Europe

The European Commission (EC) has granted orphan drug designation to NTLA-2002, an investigational gene-editing therapy that Intellia Therapeutics is developing for hereditary angioedema (HAE). The designation is given to therapies with the potential to improve medical care for people with serious conditions that affect up to five of…